Related Experiment Video
Updated: Sep 20, 2025
Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
Increased Serum Levels of sCD206 Are Associated with Adverse Prognosis in Patients with HBV-Related Decompensated
Yue Zhang1, Nanxi Xiao1, Qi Liu1
1Department of Gastroenterology, Jiangxi Clinical Research Center for Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Insights
High levels of soluble CD206 (sCD206) in patients with Hepatitis B Virus-associated decompensated cirrhosis (HBV-DeCi) predict increased mortality. This macrophage marker offers valuable prognostic insights for HBV-DeCi patients.
Area of Science:
- Hepatology
- Immunology
- Biomarker Discovery
Background:
- Hepatitis B Virus-associated decompensated cirrhosis (HBV-DeCi) presents significant mortality risks.
- Macrophages play a crucial role in the fibrotic progression of decompensated cirrhosis.
- Soluble CD206 (sCD206), a macrophage-expressed protein, is investigated as a potential mortality predictor.
Purpose of the Study:
- To determine if serum sCD206 levels can predict mortality in patients with HBV-DeCi.
- To evaluate the prognostic value of sCD206 compared to established clinical scores.
Main Methods:
- A cohort of 382 HBV-DeCi patients were analyzed over 6-month outcomes.
- Cox regression and Kaplan-Meier analyses were used to assess sCD206 as a prognostic factor.
- Area Under the Receiver Operating Characteristic (AUROC) curves evaluated sCD206's predictive accuracy.
Main Results:
- Serum sCD206 levels were significantly higher in non-surviving patients.
- Elevated sCD206 independently predicted increased 28-day, 3-month, and 6-month mortality (HR > 3.9, P < 0.001).
- sCD206 demonstrated strong predictive performance (AUROC > 0.78) at all time points.
Conclusions:
- Serum sCD206 is a significant predictor of mortality in HBV-DeCi patients.
- Higher sCD206 levels are associated with a poorer prognosis.
- sCD206 offers superior short- and midterm mortality prediction compared to CTP and MELD scores.
Background:
HBV-associated decompensated cirrhosis (HBV-DeCi) is attracting considerable attention due to disease acceleration and substantial mortality. Macrophages regulate the fibrotic process in DeCi. Soluble CD206 (sCD206) is primarily expressed by macrophages. We aimed to investigate whether sCD206 predicts mortality in patients with HBV-DeCi.
Materials And Methods:
A total of 382 patients were enrolled between February 2020 and February 2021 and divided into nonsurviving and surviving groups according to 28-day, 3-month, and 6-month outcomes. Cox regression analysis was performed to confirm the independent prognostic factors of HBV-DeCi, and Kaplan-Meier analysis was performed to draw survival curves of sCD206. The predictive value of sCD206 was assessed at three time points according to the AUROC.
Results:
The serum sCD206 level was significantly higher in deceased patients than surviving patients. Multivariate analysis showed that the level of sCD206 was related to an increased risk of 28-day, 3-month, and 6-month mortality (HR = 3.914, P < 0.001; HR = 3.895, P < 0.001; and HR = 4.063, P < 0.001, respectively). Patients with higher sCD206 levels had a worse prognosis than those with lower sCD206 levels. The best separation between the decedents and survivors was obtained by using the sCD206 level (AUROC: 0.830, 0.802, and 0.784, respectively) at 28 days, 3 months, and 6 months.
Conclusion:
The macrophage-related marker serum sCD206 was associated with mortality in HBV-DeCi patients. High levels of serum sCD206 indicated a poor prognosis in these patients. Serum sCD206 has great predictive value for short-term and midterm mortality compared with the Child-Turcotte-Pugh (CTP) and model for end-stage liver disease (MELD) scores.
